Fintel reports that on January 7, 2025, TD Cowen initiated coverage of CG Oncology (NasdaqGS:CGON) with a Buy recommendation.

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene ...

CG Oncology, Inc. (CGON – Research Report) received a Buy rating and price target from TD Cowen analyst Tyler Van Buren today. The company’s ...

CG Oncology closed a public offering of 9.2 million shares, raising $238 million for bladder cancer therapy development. CG Oncology, Inc., a clinical biopharmaceutical company specializing in ...

CG Oncology announces public offering of 8,000,000 shares at $28 each, expected to raise $204.4 million. CG Oncology, Inc. has announced the pricing of its public offering of 8 million shares of ...

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) shares were down 6.9% during mid-day trading on Monday . The stock traded as low as $27.84 and last traded at $27.98. Approximately 108,925 shares ...

CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock. Discover Fast ...

CG Oncology, Inc. (NASDAQ:CGON) reported positive results just about a week ago from its phase 3 BOND-003 study using its oncolytic immunotherapy candidate Cretostimogene for the treatment of BCG ...

CG Oncology Inc. IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a ...

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) rose 2.5% during trading on Friday . The stock traded as high as $29.90 and last traded at $29.85. Approximately 328,509 shares changed ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

CG Oncology Inc. IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a ...